Inflammatory Arthritis due to Immune Checkpoint Inhibitors
The introduction of immune checkpoint inhibitors (ICIs) has changed the landscape of the treatment of cancer. Several immune-related adverse events (irAEs) have now been described such as ICI-inflammatory arthritis (IA), sicca syndrome, polymyalgia rheumatica, myositis, and vasculitis as a consequence of immune activation. The onset of the ICI-IA can vary from after the first infusion of ICIs to a delayed presentation a year or more after ICI initiation. Ultimately, baseline patient and tumor characteristics, the types of immunotherapies used, pre-existing autoimmune diseases, and/or other irAEs, as well as patient preferences will all shape the discussions around ICI-IA management.
Source: Rheumatic Disease Clinics of North America - Category: Rheumatology Authors: Namrata Singh, Anupama Shahane, Jeffrey A. Sparks, Samuel Bitoun, Laura C. Cappelli Source Type: research
More News: Arthritis | Autoimmune Disease | Cancer | Cancer & Oncology | Immunotherapy | Polymyalgia Rheumatica | Rheumatology | Vasculitis